MAP2K1 and RASopathy: Although mutations in human MEK1 genes have been identified in RASopathies, and the early application of a MEK1 inhibitor in animal models has been able to ameliorate associated defects [10–13], there is no direct evidence indicating how MEK1 may contribute to CHD.